ELV INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Elevance Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Elevance Health class action lawsuit – captioned Miller v. Elevance Health, Inc., No. 25-cv-00923 (S.D. Ind.) – seeks to represent purchasers of Elevance Health, Inc. (NYSE: ELV) common stock and charges Elevance Health as well as certain of Elevance Health's executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Elevance Health class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-elevance-health-inc-class-action-lawsuit-elv.html
You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. Lead plaintiff motions for the Elevance Health class action lawsuit must be filed with the court no later than July 11, 2025.
CASE ALLEGATIONS: Elevance Health operates as a health benefits company. Among other things, the cost of providing health benefits to members is driven by the level of care a patient requires, often referred to as 'acuity,' and the members' utilization of the health benefits, according to the complaint.
The Elevance Health class action lawsuit alleges that defendants throughout the class period made false and/or misleading statements and/or failed to disclose that: (i) Medicaid redeterminations were causing the acuity and utilization of Elevance Health's Medicaid members to rise significantly, as the members being removed from Medicaid programs were, on average, healthier than those who remained eligible for the programs; and (ii) this shift was occurring to a degree that was not reflected in Elevance Health's rate negotiations with the states or in its financial guidance for 2024.
The Elevance Health class action lawsuit further alleges that on July 17, 2024, Elevance Health revealed that it was now 'expecting second half utilization to increase in Medicaid' and that it was 'seeing signs of increased utilization across the broader Medicaid population, including in outpatient home health, radiology, durable medical equipment as well as some elective procedures.' On this news, the price of Elevance Health stock fell nearly 6%, according to the complaint.
Then, on October 17, 2024, the Elevance Health class action lawsuit further alleges that Elevance Health announced its financial results for the third quarter of 2024, revealing that Elevance Health had missed consensus earnings per share ('EPS') expectations for the quarter by $1.33, or 13.7%, 'due to elevated medical costs in [its] Medicaid business.' Elevance Health further revealed that it was lowering EPS guidance for 2024 from $37.20 to $33.00, or 11.3%, as it expected these Medicaid issues to continue, according to the complaint. The Elevance Health class action lawsuit alleges that on this news, the price of Elevance Health stock fell nearly 11%.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Elevance Health common stock during the class period to seek appointment as lead plaintiff in the Elevance Health class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Elevance Health class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Elevance Health class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Elevance Health class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
https://www.rgrdlaw.com/services-litigation-securities-fraud.html
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Contact:
Robbins Geller Rudman & Dowd LLP
J.C. Sanchez, Jennifer N. Caringal
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Braze Reports Fiscal First Quarter 2026 Results
Hires Seasoned Veteran SaaS Revenue Leader as Chief Revenue Officer Completes acquisition of OfferFit, an AI decisioning company NEW YORK, June 05, 2025--(BUSINESS WIRE)--Braze (Nasdaq: BRZE) the leading customer engagement platform that empowers brands to Be Absolutely Engaging™, today announced results for its fiscal quarter ended April 30, 2025. "We are off to a good start in fiscal year 2026, delivering strong revenue growth, profitability, and free cash flow in an ever-changing environment," said Bill Magnuson, Cofounder and CEO of Braze. "I'm also excited to announce that Ed McDonnell will be joining Braze in July to lead all aspects of our global revenue operations. McDonnell has a strong track record of delivering results at high-growth public SaaS businesses, and we believe his extensive background in Software and Customer Engagement will further solidify Braze as the leading customer engagement platform and accelerate growth in the coming years." Fiscal First Quarter 2026 Financial Highlights Revenue was $162.1 million compared to $135.5 million in the first quarter of the fiscal year ended January 31, 2025, up 19.6% year-over year, driven primarily by new customers, upsells, and renewals. Subscription revenue in the quarter was $154.9 million compared to $130.1 million in the first quarter of the fiscal year ended January 31, 2025, and professional services and other revenue was $7.2 million compared to $5.4 million in the first quarter of the fiscal year ended January 31, 2025. Remaining performance obligations as of April 30, 2025 were $829.3 million, of which $522.2 million is current, which the company defines as less than one year. GAAP gross margin was 68.6% compared to 67.1% in the first quarter of the fiscal year ended January 31, 2025. Non-GAAP gross margin was 69.3% compared to 67.9% in the first quarter of the fiscal year ended January 31, 2025. Dollar-based net retention for all customers for the trailing 12 months ended April 30, 2025 and April 30, 2024 was 109% and 117%, respectively; dollar-based net retention for customers with annual recurring revenue (ARR) of $500,000 or more was 112% compared to 119% in the first quarter of the fiscal year ended January 31, 2025. Total customers increased to 2,342 as of April 30, 2025 from 2,102 as of April 30, 2024; 262 of the company's customers had ARR of $500,000 or more as of April 30, 2025, compared to 212 customers as of April 30, 2024. GAAP operating loss was $40.2 million compared to an operating loss of $40.1 million in the first quarter of the fiscal year ended January 31, 2025. A primary contributor to the operating loss in the quarter included $30.4 million of stock-based compensation expense. Non-GAAP operating income was $2.8 million compared to a loss of $10.0 million in the first quarter of the fiscal year ended January 31, 2025. GAAP net loss per share attributable to Braze common stockholders, basic and diluted, of $0.34 based on 104.6 million weighted average shares outstanding in the first quarter of the fiscal year ended January 31, 2026, compared to GAAP net loss per share attributable to Braze common stockholders, basic and diluted, of $0.35, based on 100.8 million weighted average shares outstanding in the first quarter of the fiscal year ended January 31, 2025. Non-GAAP net income per share attributable to Braze common stockholders, diluted, was $0.07 based on 108.0 million weighted average shares outstanding in the first quarter of the fiscal year ended January 31, 2026, compared to non-GAAP net loss per share attributable to Braze common stockholders, basic and diluted, of $0.05 based on 100.8 million weighted average shares outstanding in the first quarter of the fiscal year ended January 31, 2025. Net cash provided by operating activities was $24.1 million compared to net cash provided by operating activities of $19.4 million in the first quarter of the fiscal year ended January 31, 2025. Free cash flow was $22.9 million compared to $11.4 million in the first quarter of the fiscal year ended January 31, 2025. Total cash and cash equivalents, restricted cash, and marketable securities was $539.8 million as of April 30, 2025 compared to $514.0 million as of January 31, 2025. Recent Business Highlights Notable new business wins in the quarter included Beyond, Inc., Chamberlain Group, an intelligence access leader, Evite, Freshket, Fubo, LUSH Cosmetics, Njuškalo, and ThredUp. Closed the acquisition of AI Decisioning Engine OfferFit, which will allow brands to benefit from complementary products and frontier technologies that can transform customer relationships and deliver value to their businesses. Introduced two dynamic new messaging channels - RCS and Banners - and a new Canvas step to help marketers create more immersive and responsive customer journeys. Announced hiring of Ed McDonnell as Chief Revenue Officer, effective early July. Science Based Target Initiative officially approved Braze's near-term emissions reduction targets, reinforcing its commitment to aligning with globally recognized standards for carbon emissions reductions and further advancing Braze's sustainability program. Financial Outlook Braze is initiating guidance for the fiscal second quarter ending July 31, 2025, and updating guidance for the fiscal year ending January 31, 2026. Metric (in millions, except per share amounts) FY 2026 Q2 Guidance FY 2026 Guidance Revenue $171.0 - 172.0 $702.0 - 706.0 Non-GAAP operating income $0.5 - 1.5 $5.5 - 9.5 Non-GAAP net income $2.5 - 3.5 $17.0 - 21.0 Non-GAAP net income per share, diluted $0.02 - 0.03 $0.15 - 0.18 Weighted average common shares used in computing non-GAAP net income per share, diluted ~113.0 ~115.0 Braze has not reconciled its guidance as to non-GAAP operating income (loss), non-GAAP net income or non-GAAP net income per share to their most directly comparable GAAP measure as a result of uncertainty regarding, and the potential variability of, reconciling items such as stock-based compensation expense specific to equity compensation awards that are directly impacted by unpredictable fluctuations in Braze's stock price. Accordingly, reconciliations are not available without unreasonable effort, although it is important to note that these factors could be material to Braze's results calculated in accordance with GAAP. Conference Call Information: What: Braze Fiscal First Quarter 2026 Financial Results Conference CallWhen: Thursday, June 5th at 4:30 pm EDT / 1:30 pm PDTWebcast & Supplemental Data: A webcast replay will be available on Braze's investor site at Supplemental and Other Financial Information Supplemental information, including an accompanying financial presentation and other information can be accessed through Braze's investor website at Non-GAAP Financial Measures This press release and the accompanying tables contain the following non-GAAP financial measures: non-GAAP gross profit and margin, non-GAAP sales and marketing expense, non-GAAP research and development expense, non-GAAP general and administrative expense, non-GAAP operating income (loss), non-GAAP operating margin, non-GAAP net income (loss), non-GAAP net income (loss) per share, basic and diluted, and non-GAAP free cash flow. Braze defines non-GAAP gross profit and margin, non-GAAP sales and marketing expense, non-GAAP research and development expense, non-GAAP general and administrative expense, non-GAAP operating income (loss), non-GAAP operating margin, and non-GAAP net income (loss) as the respective GAAP balances, adjusted for stock-based compensation expense, employer taxes related to stock-based compensation, charitable contribution expense, contingent consideration adjustments, acquisition related expense, and amortization of intangible assets. Braze defines non-GAAP free cash flow as net cash provided by (used in) operating activities, minus purchases of property and equipment and minus capitalized internal-use software costs. Investors are encouraged to review the reconciliation of these historical non-GAAP financial measures to their most directly comparable GAAP financial measures. Braze uses this non-GAAP financial information internally in analyzing its financial results and believes that this non-GAAP financial information, when taken collectively with GAAP financial measures, may be helpful to investors because it provides consistency and comparability with past financial performance and assists in comparisons with other companies, some of which use similar non-GAAP financial information to supplement their GAAP results. The non-GAAP financial information is presented for supplemental informational purposes only, and should not be considered a substitute for financial information presented in accordance with generally accepted accounting principles in the United States (GAAP), and may be different from similarly-titled non-GAAP measures used by other companies. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses that are required by GAAP to be recorded in Braze's financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by Braze's management about which expenses are excluded or included in determining these non-GAAP financial measures. A reconciliation is provided below in the financial statement tables included below in this press release for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Braze encourages investors to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, which it includes in press releases announcing quarterly and fiscal year financial results, including this press release, and not to rely on any single financial measure to evaluate Braze's business. Definition of Other Business Metrics Customer: Braze defines a customer, as of period end, as the separate and distinct, ultimate parent-level entity that has an active subscription with Braze to use its products. A single organization could have multiple distinct contracting divisions or subsidiaries, all of which together would be considered a single customer. Annual Recurring Revenue (ARR): Braze defines ARR as the annualized value of customer subscription contracts, including certain premium professional services that are subject to contractual subscription terms, as of the measurement date, assuming any contract that expires during the next 12 months is renewed on its existing terms (including contracts for which Braze is negotiating a renewal). Braze's calculation of ARR is not adjusted for the impact of any known or projected future events (such as customer cancellations, expansion or contraction of existing customers relationships or price increases or decreases) that may cause any such contract not to be renewed on its existing terms. ARR may decline or fluctuate as a result of a number of factors, including customers' satisfaction or dissatisfaction with Braze's products and professional services, pricing, competitive offerings, economic conditions or overall changes in Braze's customers' spending levels. ARR should be viewed independently of revenue and does not represent Braze's GAAP revenue on an annualized basis or a forecast of revenue, as it is an operating metric that can be impacted by contract start and end dates and renewal rates. Dollar-Based Net Retention Rate: Braze calculates dollar-based net retention rate as of a period end by starting with the ARR from a cohort of customers as of 12 months prior to such period-end (the Prior Period ARR). Braze then calculates the ARR from the same cohort of customers as of the end of the current period (the Current Period ARR). Current Period ARR includes any expansion and is net of contraction or attrition over the last 12 months, but excludes ARR from new customers in the current period. Braze then divides the total Current Period ARR by the total Prior Period ARR to arrive at the point-in-time dollar-based net retention rate. Braze then calculates the weighted average point-in-time dollar-based net retention rates as of the last day of each month in the current trailing 12-month period to arrive at the dollar-based net retention rate. Remaining Performance Obligations: The transaction price allocated to remaining performance obligations represents amounts under non-cancelable contracts expected to be recognized as revenue in future periods, and may be influenced by several factors, including seasonality, the timing of renewals, the timing of service delivery and contract terms. Unbilled portions of the remaining performance obligation are subject to future economic risks including bankruptcies, regulatory changes and other market factors. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding Braze's financial outlook for the second quarter of and the full fiscal year ended January 31, 2026 and the anticipated benefits from the acquisition of OfferFit, Inc. by Braze. These forward-looking statements are based on current expectations, estimates, forecasts and projections. Words such as "anticipate," "believe," "could," "estimate," "expect," "goal," "hope," "intend," "may," might," "potential," "predict," "project," "shall," "should," "target," "will" and variations of these terms and similar expressions are intended to identify these forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on Braze's current assumptions, expectations and beliefs and are subject to substantial risks, uncertainties, assumptions and changes in circumstances that may cause Braze's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, risks and uncertainties related to: (1) the extent to which Braze achieves anticipated financial targets; (2) the impact of management and organizational changes on OfferFit's business; (3) the impact on OfferFit employees and Braze's ability to retain key personnel; (4) the effectiveness in integrating the OfferFit platform and operations with our business; (5) Braze's ability to realize its broader strategic and operating objectives; (6) unstable market and economic conditions may have serious adverse consequences on Braze's business, financial condition and share price; (7) Braze's recent rapid revenue growth may not be indicative of its future revenue growth; (8) Braze's history of operating losses; (9) Braze's limited operating history at its current scale; (10) Braze's ability to successfully manage its growth; (11) the accuracy of estimates of market opportunity and forecasts of market growth and the impact of global and domestic socioeconomic events on Braze's business; (12) Braze's ability and the ability of its platform to adapt and respond to changing customer or consumer needs, requirements or preferences; (13) Braze's ability to attract new customers and renew existing customers; (14) the competitive markets in which Braze participates and the intense competition that it faces; (15) Braze's ability to adapt and respond effectively to rapidly changing technology, evolving cybersecurity and data privacy risks, evolving industry standards or changing regulations; and (16) Braze's reliance on third-party providers of cloud-based infrastructure; as well as other risks and uncertainties discussed in the "Risk Factors" section of Braze's Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 31, 2025 and other subsequent filings Braze makes with the SEC from time to time, including Braze's Quarterly Report on Form 10-Q for the fiscal quarter ended April 30, 2025 that will be filed with the SEC. The forward-looking statements included in this press release represent Braze's views only as of the date of this press release and Braze assumes no obligation, and does not intend to update these forward-looking statements, except as required by law. About Braze Braze is the leading customer engagement platform that empowers brands to Be Absolutely Engaging.™ Braze allows any marketer to collect and take action on any amount of data from any source, so they can creatively engage with customers in real time, across channels from one platform. From cross-channel messaging and journey orchestration to Al-powered experimentation and optimization, Braze enables companies to build and maintain absolutely engaging relationships with their customers that foster growth and loyalty. The company has been recognized as a 2024 U.S. News & World Report Best Companies to Work For, 2024 Best Small & Medium Workplaces in Europe by Great Place to Work®, 2024 Fortune Best Workplaces for Women™ by Great Place to Work® and was named a Leader by Gartner® in the 2024 Magic Quadrant™ for Multichannel Marketing Hubs and a Strong Performer in The Forrester Wave™: Email Marketing Service Providers, Q3 2024. Braze is headquartered in New York with 15 offices across AMER, LATAM, EMEA, and APAC. Learn more at Braze uses its Investor website at as a means of disclosing material non-public information, announcing upcoming investor conferences and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor its investor relations website in addition to following its press releases, blog posts on its website ( SEC filings and public conference calls and webcasts. BRAZE, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (in thousands, except per share amounts) Three Months Ended April 30, 2025 2024 Revenue $ 162,059 $ 135,459 Cost of revenue (1)(2) 50,857 44,548 Gross Profit 111,202 90,911 Operating expenses: Sales and marketing (1)(2) 74,127 69,827 Research and development (1)(2) 36,797 34,373 General and administrative (1)(2)(3)(4)(5)(6) 40,500 26,791 Total operating expenses 151,424 130,991 Loss from operations (40,222 ) (40,080 ) Other income, net 5,652 5,171 Loss before provision for income taxes (34,570 ) (34,909 ) Provision for income taxes 1,071 798 Net loss (35,641 ) (35,707 ) Net income (loss) attributable to redeemable non-controlling interest 145 (66 ) Net loss attributable to Braze, Inc. $ (35,786 ) $ (35,641 ) Net loss per share attributable to Braze, Inc. common stockholders, basic and diluted $ (0.34 ) $ (0.35 ) Weighted-average shares used to compute net loss per share attributable to Braze, Inc. common stockholders, basic and diluted 104,572 100,788 (1) Includes stock-based compensation as follows: Three Months Ended April 30, 2025 2024 Cost of revenue $ 1,077 $ 964 Sales and marketing 10,011 9,445 Research and development 11,336 10,832 General and administrative 7,975 7,037 Total stock-based compensation expense $ 30,399 $ 28,278 (2) Includes employer taxes related to stock-based compensation as follows: Three Months Ended April 30, 2025 2024 Cost of revenue $ 60 $ 68 Sales and marketing 413 541 Research and development 744 836 General and administrative 213 297 Total employer taxes related to stock-based compensation expense $ 1,430 $ 1,742 (3) Includes 1% Pledge charitable donation expense as follows: Three Months Ended April 30, 2025 2024 General and administrative $ 1,109 $ — (4) Includes acquisition related expense as follows: Three Months Ended April 30, 2025 2024 General and administrative $ 10,020 $ — (5) Includes amortization of intangible assets acquired in the acquisition expense as follows: Three Months Ended April 30, 2025 2024 General and administrative $ 101 $ 218 (6) Includes adjustment to the fair value of the contingent consideration liability as follows: Three Months Ended April 30, 2025 2024 General and administrative $ — $ (137 ) BRAZE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (in thousands, except share and per share amounts) April 30, 2025 January 31, 2025 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 231,499 $ 83,062 Accounts receivable, net of allowance of $3,231 and $2,563 at April 30, 2025 and January 31, 2025, respectively 86,093 95,234 Marketable securities 307,795 430,457 Prepaid expenses and other current assets 33,752 35,273 Total current assets 659,139 644,026 Restricted cash, noncurrent 530 530 Property and equipment, net 38,803 38,550 Operating lease right-of-use assets 76,060 76,147 Deferred contract costs 79,320 76,766 Goodwill 28,448 28,448 Intangible assets, net 3,029 3,130 Other assets 3,805 3,401 TOTAL ASSETS $ 889,134 $ 870,998 LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST, AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $ 1,304 $ 2,150 Accrued expenses and other current liabilities 58,269 64,189 Deferred revenue 265,015 239,976 Operating lease liabilities, current 19,275 18,162 Total current liabilities 343,863 324,477 Operating lease liabilities, noncurrent 68,036 69,278 Other long-term liabilities 2,776 2,494 TOTAL LIABILITIES 414,675 396,249 COMMITMENTS AND CONTINGENCIES (Note 13) Redeemable non-controlling interest (Note 4) 33 (112 ) STOCKHOLDERS' EQUITY Class A common stock, $0.0001 par value; 2,000,000,000 and 2,000,000,000 shares authorized as of April 30, 2025 and January 31, 2025, respectively; 91,844,313 and 87,934,059 shares issued and outstanding as of April 30, 2025 and January 31, 2025, respectively 9 8 Class B common stock, $0.0001 par value; 110,000,000 and 110,000,000 shares authorized as of April 30, 2025 and January 31, 2025, respectively; 13,022,634 and 16,017,314 shares issued and outstanding as of April 30, 2025 and January 31, 2025, respectively 1 2 Additional paid-in capital 1,095,070 1,062,613 Accumulated other comprehensive income (loss) 1,968 (926 ) Accumulated deficit (622,622 ) (586,836 ) TOTAL STOCKHOLDERS' EQUITY 474,426 474,861 TOTAL LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST, AND STOCKHOLDERS' EQUITY $ 889,134 $ 870,998 BRAZE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (in thousands) Three Months Ended April 30, 2025 2024 CASH FLOWS FROM OPERATING ACTIVITIES: Net loss (including amounts attributable to redeemable non-controlling interests) $ (35,641 ) $ (35,707 ) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation 30,643 28,620 Amortization of deferred contract costs 9,421 8,313 Depreciation and amortization 2,606 2,126 Provision for credit losses 232 668 Value of common stock donated to charity 1,109 — (Accretion) amortization of (discount) premium on marketable securities (399 ) (487 ) Non-cash foreign exchange (gain) loss 227 (295 ) Fair value adjustments to contingent consideration — (137 ) Other 9 280 Changes in operating assets and liabilities: Accounts receivable 9,108 9,876 Prepaid expenses and other current assets 3,147 (984 ) Deferred contract costs (11,870 ) (10,730 ) ROU assets and liabilities (410 ) 1,522 Other assets (403 ) 277 Accounts payable (978 ) (1,800 ) Accrued expenses and other current liabilities (7,203 ) (7,351 ) Deferred revenue 24,547 25,285 Other long-term liabilities (1 ) (81 ) Net cash provided by operating activities 24,144 19,395 CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of property and equipment (217 ) (6,915 ) Capitalized internal-use software costs (1,055 ) (1,039 ) Purchases of marketable securities (52,364 ) (59,650 ) Maturities of marketable securities 63,215 57,000 Return of principal on marketable securities 113,258 — Net cash provided by/(used in) investing activities 122,837 (10,604 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from exercise of common stock options 605 1,035 Payments of deferred purchase consideration — (2,916 ) Net cash provided by/(used in) financing activities 605 (1,881 ) Effect of foreign currency exchange rate changes on cash, cash equivalents, and restricted cash 851 (337 ) Net change in cash, cash equivalents, and restricted cash 148,437 6,573 Cash, cash equivalents, and restricted cash, beginning of period 83,592 72,131 Cash, cash equivalents, and restricted cash, end of period $ 232,029 $ 78,704 BRAZE, INC. U.S. GAAP RECONCILIATION OF NON-GAAP ADJUSTED RESULTS (in thousands, except per share amounts) The following tables reconcile each non-GAAP financial measure to its most directly comparable GAAP financial measure: Reconciliation of GAAP to Non-GAAP Gross Margin Three Months Ended April 30, 2025 2024 Gross profit $ 111,202 $ 90,911 Plus: Stock-based compensation expense 1,077 964 Employer taxes related to stock-based compensation expense 60 68 Non-GAAP gross profit $ 112,339 $ 91,943 GAAP gross margin 68.6 % 67.1 % Non-GAAP gross margin 69.3 % 67.9 % Reconciliation of GAAP to Non-GAAP Operating Expenses Three Months Ended April 30, 2025 2024 GAAP sales and marketing expense $ 74,127 $ 69,827 Less: Stock-based compensation expense 10,011 9,445 Employer taxes related to stock-based compensation expense 413 541 Non-GAAP sales and marketing expense $ 63,703 $ 59,841 GAAP research and development expense $ 36,797 $ 34,373 Less: Stock-based compensation expense 11,336 10,832 Employer taxes related to stock-based compensation expense 744 836 Non-GAAP research and development expense $ 24,717 $ 22,705 GAAP general and administrative expense $ 40,500 $ 26,791 Less: Stock-based compensation expense 7,975 7,037 Employer taxes related to stock-based compensation expense 213 297 1% Pledge charitable contribution expense 1,109 — Acquisition related expense 10,020 — Amortization of intangibles expense 101 218 Contingent consideration adjustment — (137 ) Non-GAAP general and administrative expense $ 21,082 $ 19,376 Reconciliation of GAAP to Non-GAAP Operating Income (Loss) Three Months Ended April 30, 2025 2024 Loss from operations $ (40,222 ) $ (40,080 ) Plus: Stock-based compensation expense 30,399 28,278 Employer taxes related to stock-based compensation expense 1,430 1,742 1% Pledge charitable contribution expense 1,109 — Acquisition related expense 10,020 — Amortization of intangibles expense 101 218 Contingent consideration adjustment — (137 ) Non-GAAP income (loss) from operations $ 2,837 $ (9,979 ) GAAP operating margin (24.8 )% (29.6 )% Non-GAAP operating margin 1.8 % (7.4 )% Reconciliation of GAAP to Non-GAAP Net Income (Loss) Three Months Ended April 30, 2025 2024 Net loss attributable to Braze, Inc. $ (35,786 ) $ (35,641 ) Plus: Stock-based compensation expense 30,399 28,278 Employer taxes related to stock-based compensation expense 1,430 1,742 1% Pledge charitable contribution expense 1,109 — Acquisition related expense 10,020 — Amortization of intangibles expense 101 218 Contingent consideration adjustment — (137 ) Non-GAAP net income (loss) attributable to Braze, Inc. (1) $ 7,273 $ (5,540 ) Non-GAAP net income (loss) per share attributable to Braze, Inc. common stockholders, basic $ 0.07 $ (0.05 ) Non-GAAP net income (loss) per share attributable to Braze, Inc. common stockholders, diluted $ 0.07 $ (0.05 ) Weighted-average shares used to compute net income (loss) per share attributable to Braze, Inc. common stockholders, basic 104,572 100,788 Weighted-average shares used to compute net income (loss) per share attributable to Braze, Inc. common stockholders, diluted 107,977 100,788 (1) Assumes no non-GAAP tax expenses associated with the non-GAAP adjustment due to the Company's historical non-GAAP net loss position and available deferred tax assets sufficient to offset such non-GAAP tax expense. Reconciliation of GAAP Cash Flow from Operating Activities to Non-GAAP Free Cash Flow Three Months Ended April 30, 2025 2024 Net cash provided by operating activities $ 24,144 $ 19,395 Less: Purchases of property and equipment (217 ) (6,915 ) Capitalized internal-use software costs (1,055 ) (1,039 ) Non-GAAP free cash flow $ 22,872 $ 11,441 Braze is a registered trademark of Braze, product and company names herein may be trademarks of their registered owners. View source version on Contacts Investors:Christopher FerrisIR@ (609) 964-0585 Media:Katelyn BryantPress@
Yahoo
42 minutes ago
- Yahoo
Man who let snakes bite him 200 times spurs new antivenom hope
Tim Friede was feeling particularly down on the day after the September 11 attacks, so he went to his basement and let two of the world's deadliest snakes bite him. Four days later, he woke up from a coma. "I know what it feels like to die from snakebite," Friede told AFP via video call from his home in the small US town of Two Rivers, Wisconsin. This experience might put most people off snakes entirely, but Friede simply vowed to be more careful next time. From 2000 to 2018, he allowed himself to be bitten by snakes more than 200 times. He also injected himself with their venom over 650 times. Friede endured this pain because he wanted to achieve total immunity to venom, a practice called mithridatism which should not be tried at home. After a couple of years, Friede started to believe he could be the basis for a better kind of antivenom. The former truck mechanic, who does not have a university degree, long struggled to be taken seriously by scientists. But last month, a study published in the prestigious Cell journal showed that antibodies from his blood protect against a range of snake venom. The researchers now hope Friede's hyper-immunity could even lead to the development of a universal antivenom. This would fill a major need, because currently most antivenoms only cover one or a few of the world's 600 venomous snakes. Up to 138,000 people are killed by snakebites a year, while 400,000 suffer amputations or other disabilities, according to the World Health Organization. These figures are believed to be vastly underestimated because snakebite victims typically live in poorer, remote areas. - 'Pain every time' - Friede's first bite was from a harmless garter snake when he was five years old. "I was afraid, I cried, I ran away," said Friede, now 57. Then he started bringing snakes home and hiding them in pickle jars. His mother sought counselling, but his interest in snakes persisted. Things escalated after Friede attended a class that taught him how to "milk" snakes for their venom. How antivenom is made has changed little over the last 125 years. Small doses of snake venom are injected into animals such as horses, which produce antibodies that can be extracted and used as antivenom. However this antivenom usually only works for bites from that particular species of snake -- and it includes other antibodies from horse that can cause serious side-effects including anaphylactic shock. "I thought, well, if they make antivenom in horses, why can't I just use myself as a primate?" Friede said. He started working through the venom from all the deadly species he could get his hands on, such as cobras, taipans, black mambas and rattlesnakes. "There is pain every time," he said. - 'Proud' - For years, the scientists he contacted to take advantage of his immunity refused to bite. Then in 2017, immunologist Jacob Glanville, who previously worked on universal vaccines, turned his attention towards antivenom. Glanville told AFP he had been looking for "a clumsy snake researcher who'd been bit accidentally a couple times," when he came across a video of Friede taking brutal back-to-back snake bites. When they first spoke, Glanville said he told Friede: "I know this is awkward, but I would love to get my hands on some of your blood." "I've been waiting for this call for a long time," came the response, Glanville said. The antivenom described in the Cell paper includes two antibodies from Friede's blood, as well as a drug called varespladib. It offered mice full protection against 13 of the 19 snake species tested, and partial protection for the remaining six. The researchers hope a future cocktail will cover far more snakes -- particularly vipers -- with further trials planned on dogs in Australia. Timothy Jackson of the Australian Venom Research Unit praised the immunological research, but questioned whether a human needed to be involved, pointing to synthetically developed antibodies. Glanville said the ultimate goal of his US-based firm Centivax was to develop a universal antivenom administered by something like an EpiPen, potentially produced in India to keep the costs down. Friede said he was "proud" to have made a "small difference" in medical history. Now working for Centivax, Friede stopped self-inflicting himself with venom in 2018 to save the firm from liability issues. But he hopes to get bitten by snakes again in the future. "I do miss it," he said. dl/giv
Yahoo
42 minutes ago
- Yahoo
Braze Inc (BRZE) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Revenue: $162.1 million, up nearly 20% year-over-year. Non-GAAP Operating Margin: Increased by over 900 basis points year-over-year. Non-GAAP Net Income: Over $7 million. Free Cash Flow: Nearly $23 million in the quarter. Customer Count: 2,342, up 46 sequentially and up 240 year-over-year. Large Customers ($500,000+ ARR): 262, up 24% year-over-year. Dollar-Based Net Retention: 109% overall; 112% for large customers. Non-GAAP Gross Margin: 69.3%, up from 67.9% in the prior year quarter. Non-GAAP Sales and Marketing Expenses: $64 million or 39% of revenue. Non-GAAP R&D Expense: $25 million or 15% of revenue. Non-GAAP G&A Expense: $21 million or 13% of revenue. Cash and Equivalents: Approximately $540 million. Cash Provided by Operations: $24 million. Guidance for Q2 FY2026 Revenue: $171 million to $172 million. Guidance for FY2026 Revenue: $702 million to $706 million. Warning! GuruFocus has detected 3 Warning Signs with BRZE. Release Date: June 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Braze Inc (NASDAQ:BRZE) reported strong first-quarter results with a revenue of $162.1 million, marking a nearly 20% year-over-year increase. The company achieved its fourth consecutive quarter of non-GAAP net income profitability, with over $7 million in net income and nearly $23 million in free cash flow. Customer count increased to 2,342, up 46 sequentially and 240 year-over-year, with large customers ($500,000+ ARR) rising 24% to 262. Braze Inc (NASDAQ:BRZE) successfully closed the acquisition of OfferFit, enhancing its AI capabilities and positioning it for future growth. The company continues to replace legacy marketing clouds and win against point solutions, indicating strong competitive positioning and market demand for its offerings. Despite strong results, Braze Inc (NASDAQ:BRZE) faces an uneven macroeconomic environment, which has impacted sequential growth and net retention rates. The company noted elevated churn levels, particularly in the enterprise segment, due to seasonality and macroeconomic factors. There are concerns about the impact of switching costs on enterprise deal cycles, which can delay new growth initiatives. Braze Inc (NASDAQ:BRZE) anticipates a temporary departure from its operating income margin framework due to the OfferFit acquisition, impacting short-term profitability. The company faces regional comparative weakness, particularly in Southeast Asia, affecting overall growth momentum in the APAC region. Q: When do you think the positive company-specific dynamics will start to offset the uneven macro environment, and what metrics should we track? A: Isabelle Winkles, CFO, mentioned that CRPO is sensitive to renewal volumes and isn't a leading indicator. Revenue acceleration is the key metric to watch for macro stabilization. CEO Bill Magnuson added that competitive results are strong, with good momentum in the Americas and EMEA, and efforts to manage churn are expected to improve results. Q: What is the performance or ROI delta for customers using Project Catalyst compared to traditional Canvas flows? A: Bill Magnuson, CEO, explained that Project Catalyst is in private beta, but early results from similar technologies show significant uplift. For example, a customer using reinforcement learning for decision-making saw a 5x uplift compared to manual segmentation. Project Catalyst aims to automate decision-making at higher levels, enhancing customer engagement strategies. Q: Can you discuss the linearity of the quarter and the impact of OfferFit on your business? A: Isabelle Winkles, CFO, stated that Q1 linearity was normal, with no unusual patterns. Bill Magnuson, CEO, noted that OfferFit has been integrated well, with strong customer interest and a lead-rich environment. The focus is on qualifying opportunities and scaling OfferFit's capabilities across Braze's customer base. Q: How are you pricing OfferFit, and will it integrate with Braze's AI capabilities? A: Bill Magnuson, CEO, explained that OfferFit is currently priced separately, with costs around $250,000 to $300,000 annually, including expert services. The goal is to integrate OfferFit's reinforcement learning capabilities with Braze's platform, offering a broad range of AI-driven optimization capabilities. Q: How does the new pricing and packaging model impact customer reception and overall spend levels? A: Bill Magnuson, CEO, stated that the new pricing model, which relaxes data point limits, has been well-received, reducing negotiation times and increasing flexibility for customers. It allows for more experimentation and expansion across Braze's feature set, supporting customer value creation and expansion. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
